- UME commited to offering high-quality COVID-19 services, solutions and supplies.
- To effectively end worldwide pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical.
- CareStart antigen test features 10-minute processing time, identifies acute infection, helps provide critical answers.
Despite approval and rollout of COVID-19 vaccines, experts agree that even as the pandemic dies down in the coming months, SARS-CoV-2, the virus that causes the infectious disease, is likely here for the long haul (https://ibn.fm/1idh8). United Medical Equipment Business Solutions Network (“UME”) is here for the long haul too, commited to offering high-quality COVID-19 services, solutions and supplies. Among the supplies UME currently provides is the CareStart(TM) COVID-19 Antigen Rapid POC test.
Before COVID-19 was even declared a pandemic, the CareStart COVID-19 Antigen test had been authorized for use by the Federal Drug Administration (“FDA”) under an Emergency Use Authorization (“EUA”). “Due to the highly contagious nature and global spread, SARS-CoV-2 . . . continues to have devastating impacts on healthcare systems and the world economy, including the U.S.,” states CareStart COVID-19 Antigen packaging material approved by the FDA (https://ibn.fm/BIVxs).
“To effectively end the SARS-CoV02 pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical,” the information continues. “Particularly, the identification of subclinical or asymptomatic cases is important to reduce or stop the infection because these individuals may transmit the virus. As a point-of-care test with a 10 min testing time, CareStartCOVID-19 Antigen test allows effective screening of COVID-19 infection on a large scale.”
The CareStart antigen test can be administered by authorized laboratories and at the point of care by medical professionals to detect the presence of the SARS-CoV-2 nucleocapsid protein antigen (https://ibn.fm/qCkqU). The innovative test features a 10-minute processing time, identifies acute infection with 88.4% sensitivity and 100% specificity, and helps provide critical answers about active infections to patients and healthcare workers alike.
The CareStart product is part of a UME’s comprehensive COVID-19 monitoring strategy, which was carefully designed with the assistance of medical experts and includes ongoing, data-driven COVID-19 testing. United Medical Equipment Business Solutions is committed to being the leading provider of high-quality, reliable and transparent information and resources for all, particularly veterans and seniors. The company provides essential information and products that helps the community achieve optimal health and improve their quality of life.
In addition to the CareStart COVID-19 Antigen tests, UME provides a wide array of other COVID-19 supplies and products, including sanitizers, gloves and face shields, thermometers, hoods and masks.
UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and the medical community through its robust medication management and telehealth applications. In addition, the company recognizes the importance of being socially responsible as a corporation by giving back to the world through emergency assistance grants awarded to seniors, with an emphasis on veterans, by supporting nonprofits in their missions, and by supporting the American economy by providing work-at-home opportunities.
To learn more about this company, visit www.UnitedMedSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.